Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
1.
Iran J Med Sci ; 46(2): 136-143, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33753958

RESUMO

Background: Mebudipine, a dihydropyridine calcium-channel blocker (CCB), shows greater time- and voltage-dependent inhibitory effects than nifedipine. Its significant negative chronotropic effects without having considerable negative inotropic properties may make it a suitable candidate for the pharmacotherapy of heart failure (HF). This study aimed to investigate the possible beneficial action of mebudipine in a rat model of HF. Methods: The present study carried out in the Department of Pharmacology at the Iran University of Medical Sciences during the years of 2009-2011. An experimental model of HF was induced in male Wistar rats using doxorubicin (DOX). The rats were divided into five groups with seven animals in each group: normal control group, DOX-induced HF control groups, and treatment groups. The animals were administered DOX for 15 days. A consistent deterioration occurred after a four-week rest period. The animals were then treated with intraperitoneal mebudipine (0.5 mg/kg) and intraperitoneal amlodipine (0.35 mg/kg), as well as an equal volume of distilled water for 15 days. The plasma levels of big endothelin-1 (BET-1), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), as well as the clinical status (heart rate and blood pressure), were assessed before and after treatment. Statistical analysis was performed with SPSS software using parametric and nonparametric ANOVA. Results: Mebudipine and amlodipine reversed the increased plasma BET-1 values in the treated animals when compared with the HF control group (0.103 and 0.112 vs 0.231 pg/mL, respectively). The increased plasma levels of AST, ALT, CK-MB, and LDH were also reversed in the HF animals that received mebudipine or amlodipine. Conclusion: The administration of mebudipine to HF animals, akin to amlodipine, palliated the clinical and biochemical signs of the disease in the present study. The abstract was presented in the Iranian Congress of Physiology and Pharmacology as a poster and published in the Scientific Information Database as a supplement (2015; Vol 22).


Assuntos
Doxorrubicina/efeitos adversos , Insuficiência Cardíaca/etiologia , Nifedipino/análogos & derivados , Fatores de Proteção , Animais , Pressão Sanguínea/efeitos dos fármacos , Bloqueadores dos Canais de Cálcio , Modelos Animais de Doenças , Coração/efeitos dos fármacos , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/tratamento farmacológico , Frequência Cardíaca/efeitos dos fármacos , Irã (Geográfico) , Nifedipino/farmacologia , Nifedipino/normas , Ratos , Ratos Wistar/fisiologia
2.
Clin Exp Hypertens ; 33(2): 66-76, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21309738

RESUMO

The effects of clinically relevant concentrations of anti-hypertensive agents on lipopolysaccharide (LPS)-induced interleukin-1beta (IL-1ß) secretion by polymorphonuclear leukocytes (PMNs) were investigated in vitro. Lipopolysaccharide-induced secretion of IL-1ß by PMNs from 15 hypertensive and 15 normotensive subjects after incubation with losartan, captopril, amlodipine, atenolol, and hydrochlorothiazide were assessed. IL-1ß secretion by PMNs markedly increased in hypertensive patients versus normotensive subjects. Losartan, captopril, and amlodipine caused a concentration-dependent attenuation of IL-1ß levels in both groups. Losartan, captopril, and amlodipine demonstrated marked in vitro anti-inflammatory effects at clinically relevant serum concentrations but atenolol and hydrochlorothiazide did not.


Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Anti-Hipertensivos/farmacologia , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Interleucina-1beta/sangue , Adulto , Anlodipino/farmacologia , Atenolol/farmacologia , Captopril/farmacologia , Estudos de Casos e Controles , Feminino , Humanos , Hidroclorotiazida/farmacologia , Técnicas In Vitro , Mediadores da Inflamação/sangue , Lipopolissacarídeos/farmacologia , Losartan/farmacologia , Masculino , Pessoa de Meia-Idade , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo
3.
Adv Physiol Educ ; 33(2): 121-9, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19509398

RESUMO

A modular patch-clamp amplifier was constructed based on the Strickholm design, which was initially published in 1995. Various parts of the amplifier such as the power supply, input circuit, headstage, feedback circuit, output and nulling circuits were redesigned to use recent software advances and fabricated using the common lithographic printed circuit board fabrication process and commercially available electronic components. The calibration, validation, and regular recording procedures along with the results of an actual recording of inward Ca(2+) currents from PC12 neuronal cells are described in detail. This work describes the construction of a low-cost patch-clamp amplifier and setting up an electrophysiology recording system in a laboratory with regular technical expertise. The constructed amplifier provides an inexpensive yet practical tool for research and teaching purposes while the experience obtained during construction and setting up of the patch-clamp amplifier provides the basic and advanced understanding required for operating an advanced cell potential recording apparatus.


Assuntos
Amplificadores Eletrônicos/normas , Eletrofisiologia/educação , Eletrofisiologia/normas , Técnicas de Patch-Clamp , Calibragem , Eletrofisiologia/instrumentação , Desenho de Equipamento/instrumentação , Desenho de Equipamento/normas , Humanos , Técnicas de Patch-Clamp/instrumentação , Técnicas de Patch-Clamp/normas , Reprodutibilidade dos Testes
4.
Turk J Haematol ; 26(3): 114-7, 2009 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-27265493

RESUMO

OBJECTIVE: Major thalassemia is one of the hematological diseases requiring multiple blood transfusions, which results in iron overload in the liver, heart and other organs. Current iron chelation therapy consists of intravenous (IV) deferoxamine and oral deferasirox and deferiprone. Although these chelators are effective, many side effects are reported. In the present study, the iron-chelating effect of ciprofloxacin with good oral absorption was investigated. METHODS: Thirty male albino Wistar rats were used for the study. Ciprofloxacin (7 or 14 mg/kg per day) was administered simultaneously with iron (0.03 g/kg per day) or after one-month administration of iron. Ciprofloxacin effect on iron absorption in the liver and heart was studied carefully using atomic absorption. RESULTS: A significant decrease in the liver and heart iron following the ciprofloxacin (14 mg/kg per day) administration was observed, when compared with the control group. This ciprofloxacin-induced tissue iron depletion was more pronounced when it was administered simultaneously with iron, when it was administered for a longer duration (2 months rather than 1 month) and when it was given in higher doses (14 mg/kg per day). CONCLUSION: Administration of ciprofloxacin may help to decrease the burden of parenteral administration, thereby improving compliance and also the life expectancy of thalassemic patients.

5.
J Res Med Sci ; 14(4): 205-9, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21772885

RESUMO

BACKGROUND: Patients with Alzheimer's disease (AD) reportedly exhibit hypersensitivity to much diluted tropicamide solution (0.005%), a M4 muscarinic receptor antagonist. Therefore intraocular application of 0.005% tropicamide may be useful for screening dementia. The aim of this study was to simplify the pupil response test by using a new image analyzing system, which consists of a cheap, simple, and easy to use web-camera and a computer. METHODS: Intraocular tropicamide of 0.005% concentration was administered in 3 groups: Alzheimer's disease patients (n = 8, average age = 76 ± 5), non-Alzheimer's disease elderly (n = 6, average age = 65 ± 7), and young subjects (n = 8, average age = 28 ± 5). Every 5 minutes for 60 minutes, image of the eye's shape were taken, and the diameter of the pupils was measured. RESULTS: The results showed that differences in pupil dilation rate between Alzheimer's disease and non-Alzheimer's disease subjects were statistically significant. ROC analysis showed that after 35 minutes the sensitivity and specificity of the test were 100%. CONCLUSIONS: Based on our results, we concluded that this recording system might be an appropriate and reliable tool for pupil response diagnosis test of Alzheimer's disease.

6.
J Pharm Pharm Sci ; 11(1): 22-31, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18445362

RESUMO

PURPOSE: The effects of pioglitazone on sildenafil responsiveness in men with erectile dysfunction(ED) and a history of poor response to sildenafil were assessed. METHODS: In a double-blinded study,38 men aged 47 +/- 1.5 years with moderate-to severe ED and poor response to sildenafil were randomly assigned to take a premedication of pioglitazone 30 mg (n=19) or placebo (n=19) once daily for 9 weeks along with on-demand use of sildenafil during the last month of pioglitazone treatment.Erectile function (EF) scores, assessed by EF domain of International Index of Erectile Function (IIEF), along with responses to Global Assessment Questions (GAQs) were major outcome measures. Serum levels of total testosterone (T),dehydroepiandrosterone sulfate (DHEAS), glucose,lipid profile and liver function test were minor outcome measures. RESULTS: Pioglitazone significantly improved major outcome measures compared with placebo. The decrease from baseline of total cholesterol level was more in pioglitazone than in placebo-treated groups. In 84% (32 out of 38) of the sildenafil poor-responders, at least one of the associated risk factors of ED was found. There was undiagnosed hypercholesterolemia in 34% of the subjects. Serum levels of T, DHEAS, glucose and other parameters remained unchanged in both groups. The intervention was well tolerated. CONCLUSIONS: Pioglitazone increased sildenafil response to improve ED of men with prior sildenafil failure and seems to be safe based on the present preliminary study. This improvement is likely regardless of fasting glucose and sex hormones levels.


Assuntos
Disfunção Erétil/tratamento farmacológico , Piperazinas/uso terapêutico , Sulfonas/uso terapêutico , Tiazolidinedionas/uso terapêutico , Adulto , Idoso , Método Duplo-Cego , Sinergismo Farmacológico , Disfunção Erétil/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Pioglitazona , Piperazinas/farmacocinética , Estudos Prospectivos , Purinas/farmacocinética , Purinas/uso terapêutico , Citrato de Sildenafila , Sulfonas/farmacocinética , Tiazolidinedionas/farmacocinética , Resultado do Tratamento
7.
Pathophysiology ; 15(4): 227-31, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18945602

RESUMO

The protective effect of two new L-type calcium-channel blockers, mebudipine and dibudipine on neurotoxic effects induced by glutamate and oxygen-glucose deprivation (OGD) in PC12 cells was investigated. PC12 cells were intoxicated with two different methods. First, the cells were incubated with glutamate (10muM/L), glutamate and mebudipine (10muM/L), dibudipine (10muM/L) or nimodipine (10muM/L), on three different treatment schedules (concurrently, pre-3h and pre-24h). In the second method PC12 cells were exposed to in vitro oxygen-glucose deprivation for 30min and 60min alone or with the drugs in the same time schedules described above. Cellular viability was assessed by MTT assay. Glutamate-induced cell death and OGD-induced cell injury were attenuated significantly by mebudipine, dibudipine in comparison with nimodipine in all three different treatment schedules. Application of MK801 (10muM/L), an antagonist of NMDA glutamate receptors inhibited PC12 cell death in both methods. Our study suggests that mebudipine and dibudipine, like nimodipine, may have protective effects against glutamate and oxygen-glucose deprivation-induced neurotoxicity.

8.
J Toxicol Environ Health A ; 70(13): 1125-9, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17558807

RESUMO

Paraoxonase (PON1) is a serum enzyme that plays an important role in prevention of atherosclerosis and also protects against organophosphate-induced neurotoxicity. PON1 displays a high variability in human populations. In this study, PON1-192 and -55 polymorphisms and correlation to serum PON1 activity were investigated in 132 healthy Iranian individuals from Isfahan province. The genotype frequencies for PON1-192 were approximately 48% (QQ), 42.% (QR), and 10% (RR) and for PON1-55 17% (MM), 48% (ML), and 35% (LL). Thus, the frequencies of alleles R and L were 0.31 and 0.59, respectively. PON1 activity toward paraoxon was markedly affected in both polymorphic populations in the following order QQ < QR < RR genotype for PON1-192 and MM < ML < LL genotype for PON1-55. Neither polymorphism significantly affected PON1 activity toward phenylacetate. The RR/LL individuals had the highest PON1 activity and QQ/MM individuals the least. The QR/ML haplotype was the most frequent seen in Iranians, and the RR/MM and QR/MM haplotypes were absent in this population. In conclusion, the frequencies of PON1-192 and -55 polymorphisms in this Iranian population were different from those seen in other Asian populations from Japan and China but similar to those for European Caucasians.


Assuntos
Arildialquilfosfatase/genética , Polimorfismo Genético , Adolescente , Adulto , Idoso , Arildialquilfosfatase/metabolismo , Aterosclerose/genética , Feminino , Genética Populacional , Genótipo , Humanos , Irã (Geográfico) , Masculino , Pessoa de Meia-Idade , Organofosfatos/metabolismo
9.
Basic Clin Pharmacol Toxicol ; 101(2): 104-7, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17651311

RESUMO

Human serum paraoxonase (PON1) is a high-density lipoprotein-associated esterase that protects against organophosphate neurotoxicity, and is proposed to play a role in lipid metabolism and the onset of cardiovascular disease. In the present study, paraoxonase activities and phenotype distribution in serum of 132 healthy Iranian individuals aged 17-68 years were assessed using dual substrate method. In the study population, a wide interindividual variability (up to 15-fold) of paraoxonase activity was found. The mean of basal, salt-stimulated paraoxonase and arylesterase activities were 81.8 +/- 57 U/ml, 153.1 +/- 117.5 U/ml and 80.7 +/- 12.8 kU/l, respectively. The ratio of salt-stimulated paraoxonase activity to arylesterase activity was used for definition of phenotypes. Based on the observed ratios, three distinct phenotypes AA (low activity), AB (intermediate activity) and BB (high activity) were determined. The PON1 ratio varied from 0.5 to 6.8. The paraoxonase phenotype frequencies were approximately 48% (AA), 41% (AB) and 11% (BB). In this work, serum triglycerides had significant positive correlation (r = 0.334, P < 0.05) with paraoxonase activity, whereas high-density lipoprotein did not. No significant decrease in paraoxonase activity by smoking was observed. Age and sex had no influences on PON1 activities. In conclusion, the distribution of paraoxonase phenotypes in this Iranian population was trimodal and comparable to that of Caucasians from North America; however, overall enzyme activity was lower than that reported for Caucasians.


Assuntos
Arildialquilfosfatase/genética , Hidrolases de Éster Carboxílico/metabolismo , Genética Populacional , Adolescente , Adulto , Idoso , Arildialquilfosfatase/sangue , Arildialquilfosfatase/metabolismo , Colesterol/sangue , Feminino , Humanos , Irã (Geográfico) , Masculino , Pessoa de Meia-Idade , Fenótipo , Fumar/metabolismo , Triglicerídeos/sangue
10.
J Pharmacol Toxicol Methods ; 53(3): 206-14, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16165374

RESUMO

INTRODUCTION: A new non-radioactive method based on competitive ELISA has been developed for binding studies on angiotensin II (Ang II) receptors. METHOD: Rat liver membrane was used as the source of angiotensin receptors and FITC-angiotensin II (FITC-Ang II) was used as the labeled ligand with an affinity similar to unlabeled Ang II. The effects of different concentrations of Ang II, losartan, CGP-42112A and saralasin were studied on FITC-Ang II binding. RESULTS: The Ki values for Ang II, losartan and CGP-42112A were calculated as 0.52+/-0.22 nM, 6+/-3 nM and 0.15+/-0.07 nM, respectively. Saralasin inhibited the binding of labeled ligand biphasically, revealing two different populations of Ang receptor with different affinities for saralasin. About 74% of the binding sites were more sensitive to saralasin with a Ki value of 0.32+/-0.04 nM while saralasin showed a Ki value of 2.7+/-0.8 nM for the remaining binding sites. DISCUSSION: The competitive ELISA method developed in this work yields Ki values for angiotensin antagonists similar to those obtained by others using radiolabeled ligands. The simplicity of this method makes it a suitable alternative to radioligand studies for routine analysis of interaction of drugs with angiotensin receptors.


Assuntos
Angiotensina II/antagonistas & inibidores , Fígado/efeitos dos fármacos , Receptores de Angiotensina/metabolismo , Angiotensina II/análogos & derivados , Angiotensina II/metabolismo , Angiotensina II/farmacologia , Antagonistas de Receptores de Angiotensina , Animais , Sítios de Ligação/efeitos dos fármacos , Ligação Competitiva , Bioensaio , Membrana Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ensaio de Imunoadsorção Enzimática , Fluoresceína-5-Isotiocianato/metabolismo , Técnica Indireta de Fluorescência para Anticorpo , Corantes Fluorescentes/metabolismo , Técnicas In Vitro , Cinética , Ligantes , Fígado/citologia , Losartan/farmacologia , Masculino , Modelos Imunológicos , Oligopeptídeos/farmacologia , Ratos , Ratos Wistar , Saralasina/farmacologia , Vasoconstritores/farmacologia , Vasodilatadores/farmacologia
11.
Pathophysiology ; 13(2): 67-9, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16490349

RESUMO

Cardiac attacks and sudden cardiac deaths are more common in cold seasons. Up to now the underlying pathophysiologic mechanism of the seasonal variation in cardiovascular accidents is scarcely known. There are many physiological mechanisms which exhibit seasonal variation (e.g. blood pressure). Nitric oxide (NO) is a potent vasodilator, and impaired responsiveness to its physiological effects has been reported in many pathological situations including cardiovascular accidents. The aim of the present study was to evaluate the role of NO-dependent mechanisms on seasonal variation in aortic relaxation in vitro in rats. Male Sprague-Dawley rats grown up in different seasons in natural light/dark situation were used in the study, while the temperature and humidity were kept constant throughout the study (22+/-1 degrees C). The in vitro aortic ring responsiveness to an NO donor was studied in different seasons. Intact and denuded rings were pre-contracted with phenylephrine and vaso-relaxatory response to sodium isosorbide dinitrate (10(-8) to 10(-4)M) was recorded in vitro. The vaso-relaxatory response to isosorbide dinitrate (10(-6)M) was higher in aortic rings obtained in summer compared with those in winter and fall. There was a significant difference in EC(50) of sodium isosorbide dinitrate-induced vaso-relaxation of rings obtained from rats which were grown up in summer and winter (EC(50): 2.23+/-0.069 versus 4.31+/-0.088, P<0.05). The maximum response (R(max)) to isosorbide dinitrate was, however, identical in rings obtained from these rats. In conclusion, the in vitro responsiveness of aorta to NO is affected by seasonal light/dark periods the rats are exposed. This might be one of the reasons why more sudden cardiac deaths occur also in humans during winter.

12.
Iran J Pharm Res ; 15(2): 501-12, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27642321

RESUMO

In the present work we set out to investigate the neuroprotective effects of noscapine (0.5-2 µM) in presence of D-glucose on primary murine foetal cortical neurons after oxygen-glucose deprivation/24 h. recovery. Cell viability, nitric oxide production and intracellular calcium ((ca(2+))i) levels were evaluated by MTT assay, the modified Griess method and Fura-2 respectively. 25 and 100 mM D-glucose could, in a concentration dependent manner, improve cell viability and decrease NO production and (ca(2+))i level in neuronal cells after ischemic insult. Moreover, pre-incubation of cells with noscapine, noticeably enhanced protective effects of 25 and 100 mM D-glucose compared to similar conditions without noscapine pre-treatment. In fact, noscapine attenuated NO production in a dose-dependent fashion, after 30 minutes (min) OGD, during high-glucose (HG) condition in cortical neurons. Pretreatment with 2 µM noscapine and 25 or 100 mM D-glucose, was shown to decrease the rise in (ca(2+))i induced by Sodium azide/glucose deprivation (chemical OGD) model. These effects were more pronounced than that of 25 or 100 mM D-glucose alone. The present study demonstrated that the neuroprotective effects of HG before an ischemic insult were augmented by pre-treatment with noscapine. Our results also suggested that the neuroprotection offered by both HG and noscapine involve attenuation of NO production and (ca(2+))i levels stimulated by the experimental ischemia in cortical neurons.

13.
Phytochemistry ; 66(13): 1581-92, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15949825

RESUMO

Spinal-Z, a methanolic mixture of dried powdered seeds of Peganum harmala Linn. and leaf of Dracocephalum kotschyii Boiss. is an Iranian ethno-medical remedy. It has been used for the treatment of various types of cancer for many years. To evaluate the use of Spinal-Z in treatment of cancer, we examined its effects against a panel of malignant cell lines and tumors induced in mice. The in vitro antiproliferative activities of Spinal-Z, the seed extract of P. harmala and the leaf extract of D. kotschyii were determined using the MTT assay. The concentration of the agent required to inhibit cell growth by 50% (IC50) was estimated. In addition, the anti-tumor activities of the remedy and its constituents were investigated. Viability of cells treated with Spinal-Z and its components decreased in a dose dependent manner. Spinal-Z and its components showed cytotoxic effects against all cell lines tested. The leaf extract of D. kotschyii showed a greater preferential cytotoxic effect than the seed extract of P. harmala and Spinal-Z, on all cell lines tested. Harmine showed cytotoxicity against HL60 and K562 cell lines. This could explain the cytotoxic effect of P. harmala on these cells. The leaf extract of D. kotschyii was able to inhibit tumor proliferation in mice. The active ingredient in the leaf extract of D. kotschyii appears to be a flavone identified as xanthomicrol. Xanthomicrol was able to inhibit proliferation of a number of malignant cells. The cytotoxic effects of xanthomicrol were more selective towards malignant cells than doxorubicin.


Assuntos
Antineoplásicos Fitogênicos/química , Flavonas/química , Lamiaceae/química , Animais , Antineoplásicos Fitogênicos/toxicidade , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Doxorrubicina/toxicidade , Flavonas/toxicidade , Células HL-60 , Harmina/isolamento & purificação , Harmina/toxicidade , Humanos , Camundongos , Extratos Vegetais/química , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/toxicidade , Folhas de Planta/química , Plantas Tóxicas/química , Sementes/química
14.
Pharmacol Rep ; 67(2): 281-8, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25712651

RESUMO

BACKGROUND: The present study aims to investigate the effect of noscapine (0.5-2.5 µM), an alkaloid from the opium poppy, on primary murine fetal cortical neurons exposed to oxygen-glucose deprivation (OGD), an in vitro model of ischemia. METHODS: Cells were transferred to glucose-free DMEM and were exposed to hypoxia in a small anaerobic chamber. Cell viability and nitric oxide production were evaluated by MTT assay and the Griess method, respectively. RESULTS: The neurotoxicities produced by all three hypoxia durations tested were significantly inhibited by 0.5 µM noscapine. Increasing noscapine concentration up to 2.5 µM produced a concentration-dependent inhibition of neurotoxicity. Pretreatment of cells with MK-801 (10 µM), a non-competitive NMDA antagonist, and nimodipine (10nM), an L-type Ca(2+) channel blockers, increased cell viability after 30 min OGD, while the application of NBQX (30 µM), a selective AMPA-kainate receptor antagonist partially attenuated cell injury. Subsequently, cells treated with noscapine in the presence of thapsigargin (1 µM), an inhibitor of endoplasmic reticulum Ca(2+) ATPases. After 60 min OGD, noscapine could inhibit the cell damage induced by thapsigargin. However, noscapine could not reduce cell damage induced by 240 min OGD in the presence of thapsigargin. Noscapine attenuated nitric oxide (NO) production in cortical neurons after 30 min OGD. CONCLUSIONS: We concluded that noscapine had a neuroprotective effect, which could be due to its interference with multiple targets in the excitotoxicity process. These effects could be mediated partially by a decrease in NO production and the modulation of intracellular calcium levels.


Assuntos
Isquemia Encefálica/metabolismo , Isquemia Encefálica/prevenção & controle , Glucose/deficiência , Hipóxia/tratamento farmacológico , Hipóxia/patologia , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Noscapina/farmacologia , Animais , Isquemia Encefálica/tratamento farmacológico , Isquemia Encefálica/patologia , Sobrevivência Celular/efeitos dos fármacos , Maleato de Dizocilpina/farmacologia , Relação Dose-Resposta a Droga , Hipóxia/metabolismo , Camundongos , NG-Nitroarginina Metil Éster/farmacologia , Neurônios/metabolismo , Neurônios/patologia , Fármacos Neuroprotetores/uso terapêutico , Nimodipina/farmacologia , Óxido Nítrico/metabolismo , Noscapina/uso terapêutico , Cultura Primária de Células , Quinoxalinas/farmacologia , Tapsigargina/farmacologia
15.
Iran J Neurol ; 14(1): 12-6, 2015 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-25874051

RESUMO

BACKGROUND: Massive ischemic stroke causes significant mortality and morbidity in stroke patients. The main treatments for massive ischemic stroke are recombinant tissue plasminogen activator (rtPA), craniotomy, and endovascular interventions. Due to destructive effects of bradykinin on the nervous system in ischemic stroke, it seems reasonable that using Noscapine as a Bradykinin antagonist may improve patients' outcome after ischemic stroke. The effect of Noscapine on massive ischemic stroke was shown by the previous pilot study by our group. This pseudo-randomized clinical trial study was designed to assess the result of the pilot study. METHODS: Patients who had clinical symptoms or computed tomography scan indicative of massive stroke (in full middle cerebral artery territory) were entered to the study. The cases received the drugs according to their turns in emergency ward (pseudo-randomized). The patient group received Noscapine, and the control group received common supportive treatments. The patients and data analyzer were blinded about the data. At the end of the study, to adjust confounding variables we used logistic regression. RESULTS: After 1-month follow-up, 16 patients in the control group and 11 patients in the case group expired (P = 0.193). Analyzing the data extracted from Rankin scale and Barthel index check lists, revealed no significant differences in the two groups. CONCLUSION: Despite the absence of significant statistical results in our study, the reduction rate of 16% for mortality rate in Noscapine recipients is clinically remarkable and motivates future studies with larger sample sizes.

16.
J Pharm Pharm Sci ; 5(1): 19-23, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12042115

RESUMO

PURPOSE: Peganum harmala L. (Zygophyllaceae) seeds extract is one of the main components of an ethnobotanical preparation used in the treatment of neoplasms in Iran. Cytotoxic effects of P. harmala extract on cancerous cell-lines have been reported before. beta-carbolines like harmaline and harmine are the major alkaloids present in the seeds of the P. harmala. Considering reports concerning DNA topoisomerase inhibition by other beta-carbolines like harmane, we have used DNA relaxation assays to investigate topoisomerase I inhibitory activity of P. harmala seeds extract and its beta-carboline alkaloids to further inspecting the mechanism of its cytotoxic activity. METHODS: Harmine and harmaline contents of the extract were determined using an HPTLC method. DNA topoisomerase I enzyme needed for investigating inhibitory effect of the compounds using DNA relaxation assay, was partially purified from the human placenta. DNA relaxation assay is based on the conversion of a supercoiled plasmid substrate to its relaxed form by the catalytic activity of the enzyme. The supercoiled substrate and its relaxed product can be easily distinguished using agarose gel electrophoresis, since the relaxed topological isomers of DNA migrate more slowly than supercoiled species. RESULTS: Using HPTLC method, it was found that each gram of dried extract contained 55.5 and 79.0 mg of harmine and harmaline respectively. In the DNA relaxation assay, order of potency was harmine > harmane > harmaline > extract. The most active compound was harmine with IC50 value of 13.5 +/- 1.7 microg/ml. CONCLUSIONS: Our in vitro findings demonstrate that P. harmala seeds extract do inhibit human DNA topoisomerase I and based on the results of HPTLC analysis, it appears that the biological activity of the extract can be explained by its beta-carboline content.


Assuntos
DNA Topoisomerases Tipo I/metabolismo , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/farmacologia , Extratos Vegetais/farmacologia , Inibidores da Topoisomerase I , Zygophyllaceae/química , Cromatografia Líquida de Alta Pressão/métodos , DNA/metabolismo , DNA Topoisomerases Tipo I/isolamento & purificação , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Humanos , Placenta/enzimologia , Sementes/química
17.
J Pharm Pharm Sci ; 6(3): 346-51, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14738715

RESUMO

PURPOSE: To develop a HPLC method for assay of dibudipine in biological fluids and to study its pharmacokinetics in the rat. METHODS: HPLC: 2 microl (20 microg/ml) mebudipine as internal standard, 0.2 ml NaOH 1 M and 2 ml ethyl acetate were added to 0.2 ml of rat plasma. The mixture was shaken for 10 min, centrifuged, and the supernatant was dried under nitrogen. The dissolved residue was injected to a C18 analytical column. Mobile phase flowed at 1 ml/min with a composition of methanol--water-acetonitrile (70-25-5). The eluent was monitored at 238 nm. Pharmacokinetic study: plasma samples were collected periodically after intravenous (0.5 mg/kg) or oral (10 mg/kg) administration of dibudipine to rats (n = 4/group). In addition, separate groups of animals were administered 0.5 mg/kg doses of the drug for serial collection of brain, heart, kidney and liver (n = 4/time). The concentration of the drug in tissue or plasma was assayed using the above HPLC method. RESULTS: Calibration curves were linear over a concentration of 10-1000 ng/ml and CV was less than 10%. Dibudipine showed a bi-exponential decline after IV injection in the rats with a t1/2 beta of 2.5 +/- 0.5(mean +/- SE) hr. Oral bioavailability was low. Distribution of dibudipine to the examined tissues was rapid, and with the exception of the brain, the concentrations of the drug in all tissues were higher than the plasma levels CONCLUSIONS: The HPLC method was simple and convenient. Moreover, it could be applied to investigations of the pharmacokinetics of dibudipine in the rat.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Nifedipino/análogos & derivados , Nifedipino/farmacocinética , Animais , Disponibilidade Biológica , Masculino , Nifedipino/sangue , Ratos , Ratos Sprague-Dawley
18.
J Pharm Biomed Anal ; 30(4): 1379-84, 2002 Nov 07.
Artigo em Inglês | MEDLINE | ID: mdl-12408929

RESUMO

Permethrin, a highly effective insecticide agent, has been widely used for the pest control in agriculture and the treatment of lice in human. A fast and reliable method for the determination of permethrin was highly desirable to support formulation screening and quality control. A second-derivative UV spectroscopic method was developed for the determination of permethrin in the shampoo dosage form after extraction. The second-derivative spectrum recorded between 250 and 310 nm, and a zero-crossing technique for second-derivative measurement at 279 nm was selected. It is found that the selectivity and sensitivity of the method to be in desirable range. In comparison with the direct UV method, second-derivative UV spectroscopy eliminates the interference from UV absorbing excipients. This method is also fast and economical in comparison with the more time-consuming GC method regularly used for formulation screening and quality control and can be used routinely by any laboratory possessing a spectrophotometer with a derivative accessory. The linear concentration ranges were 0.25-1.5 ppm (D2=0.00042Conc.+0.0018, r=0.9972, n=10). Between day of CV%

Assuntos
Preparações para Cabelo/análise , Permetrina/análise , Espectrofotometria Ultravioleta/métodos
19.
Farmaco ; 58(11): 1193-9, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14572871

RESUMO

In the current study, four new 2-alkyl-N-biphenyl fused imidazoles were synthesized and the pharmacological properties of these compounds as angiotensin II antagonists were studied. First, the potency of the synthesized compounds on guinea-pig ileum was evaluated and the vasopressor effect of the most potent compound 6a was compared with losartan on isolated perfused rat kidney. The antagonistic activity of compound 6a (sodium 2-propyl-5-carbomethoxy-1-[(biphenyl-4-yl)methyl]pyrrolo[3,2-d]imidazole-2'-carboxylate) on angiotensin II receptors was greater than the other synthesized compounds and in isolated perfused rat kidney was similar to losartan.


Assuntos
Antagonistas de Receptores de Angiotensina , Imidazóis/síntese química , Imidazóis/farmacologia , Angiotensina II/farmacologia , Animais , Relação Dose-Resposta a Droga , Cobaias , Masculino , Ratos , Ratos Wistar , Receptores de Angiotensina/fisiologia , Vasoconstrição/efeitos dos fármacos , Vasoconstrição/fisiologia
20.
Arch Med Sci ; 9(1): 146-50, 2013 Feb 21.
Artigo em Inglês | MEDLINE | ID: mdl-23516061

RESUMO

INTRODUCTION: Relevant aspects of Alzheimer's disease (AD) can be modeled by aluminium-maltolate injection into specific regions of the brain. The possible role of berberine chloride (BC) as an anti-inflammatory agent in the brain has been previously addressed. MATERIAL AND METHODS: Rabbits were divided into control (C), untreated lesion (L) and BC-treated + lesion (L + BC) groups. Animals in L + BC received BC (50 mg/ kg) orally 1 day after surgery and daily for 2 weeks. The lesion was induced by injection of 100 µl of either vehicle or water containing 25 mM aluminium-maltol into intraventricular fissure. Weight loss, ataxia, paralysis and tremor were monitored. For histopathology, Bielschowsky silver and H&E staining were employed. ß-Secretase activity in hippocampus was finally assessed. RESULTS: All L animals died on days 12-15 after lesion. Seven to 10 days after lesion, abnormal symptoms as well as cachexia were seen in over 90% of cases. L rabbits lost an average of 0.5 kg which was significant on days 10 and 12 (p < 0.05); this was not completely prevented by BC. Up to day 15, all L animals had lost their lives (p < 0.001). BC treatment protected the hippocampus from degeneration, altered the behavior and decreased the activity of ß-site amyloid precursor protein cleaving enzyme-1 (BACE-1). CONCLUSIONS: Considering the findings in regard to physiological abilities, histological changes and BACE-1 activity in hippocampus changes, it is concluded that BC treatment could be an effective therapy in restoring Al maltol-induced behavioral derangements in the rabbit model of AD.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA